Lisanti Capital Growth’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
VPM
VCM
NAMI
CC
Lisanti Capital Growth's LGND Position: Q1 2026 in Review
Lisanti Capital Growth reduced its Ligand Pharmaceuticals (LGND) stake by 12% in Q1 2026, selling an estimated $1.01M and leaving 38,612 shares worth $7.71M. The position accounts for 1.94% of the portfolio, ranked #8.
Lisanti Capital Growth first reported a position in LGND in Q2 2013 and has held it in 17 quarters since. The position peaked at $8.27M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Lisanti Capital Growth held 38,612 shares of Ligand Pharmaceuticals worth $7.71M as of Q1 2026.
- Lisanti Capital Growth sold 5,130 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.01M.
- Ligand Pharmaceuticals made up 1.94% of Lisanti Capital Growth's portfolio in Q1 2026, its #8 holding.
- Lisanti Capital Growth first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
- Lisanti Capital Growth's Ligand Pharmaceuticals position peaked at $8.27M in Q4 2025.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.